Abstract
Establishing Credibility Ensures Success for Drug Discovery Contract
Research Companies
Industry participants that provide the specialized knowledge and superior
standard of research required for drug discovery will attract global sponsorship
and gain a head start in the current competitive scenario. This credibility can
be built with an impressive history of previous contract research work
completed, with emphasis on the type of work, its quality, and the sponsor
involved. Superior domain expertise, technical skill sets of people, and high
quality manpower and infrastructure will go a long way toward establishing
relationships with companies that are looking to partner with the best in the
field. Since global drug discovery majors prefer platform technologies,
companies with validated and robust technology platforms will enjoy sustained
growth.
This new research service from Frost & Sullivan provides a comprehensive
analysis of the global drug discovery contract research opportunities in ten
leading market segments. Based on the expected impact of identified drivers,
restraints, challenges, and trends, market analysis is provided for each
segment. This study also provides an overview of drug discovery outsourcing and
market dynamics, along with cumulative basic research on outsourcing payouts for
each of the segments. Profiles of numerous alliances in these segments
facilitate growth strategies for established industry participants and new
entrants.
Developing Viable Partnerships Can Increase Profits
"Many strategies have been adopted to bolster the sagging research
productivity; however, the single most important strategy is outsourcing of drug
discovery to optimize resources," says the analyst of this research
service. The tremendous pressure on drug discovery companies to increase
research productivity and accelerate the rate at which new products are
introduced have made them look toward contract research companies to achieve
this goal. These research companies prove more cost-effective and have
interesting technologies that can augment drug discovery.
"Drug discovery contract research companies in search of success in the
near future need to necessarily ensure that they strategically fit the
outsourcing needs of global biotech and pharma majors," adds the author.
Overcoming hurdles such as prohibitive investments in infrastructure, manpower,
and technologies will enable aspiring companies to dominate the contract
research space.
Technology Platforms Attract Lucrative Drug Discovery Alliances
Drug discovery companies prefer companies that have the added advantage of
technology platforms in first-generation genomics, genomic targets, genomic
supply, chemistry, screening, and gene therapy. This has led to companies
increasingly focusing on developing proprietary technology and forming an
alliance with a global outsourcer of drug discovery.
However, smaller biotech and pharmaceutical companies and public-funded
research institutions that cannot afford the investments in infrastructure,
manpower, and technology cannot emulate the movement up the value chain from
chemistry to developing proprietary technology. The capital-intensive nature and
domain expertise involved ensures that they remain only in the chemistry-related
and screening segments.
View Cart
